-
Respiratory syncytial virus vaccines: the future is bright Lancet Respir. Med. (IF 38.7) Pub Date : 2024-06-05 The Lancet Respiratory Medicine
-
Protecting respiratory health of athletes: an Olympic challenge Lancet Respir. Med. (IF 38.7) Pub Date : 2024-06-05 James H Hull, Hege Clemm, Vibeke Backer, Michael Koehle, Margo Mountjoy, Martin Schwellnus, J Tod Olin
-
Living with spinal muscular atrophy while working in critical care Lancet Respir. Med. (IF 38.7) Pub Date : 2024-06-05 Linsey Wehner, Atul Malhotra, Jeremy Orr
-
Paediatric anaesthesia: it is not only what you do, but how you do it Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-21 Thomas Engelhardt, Nicola Disma
-
High-flow nasal oxygen for children's airway surgery to reduce hypoxaemic events: a randomised controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-21 Susan Humphreys MBBCH FANZCA, Prof Britta S von Ungern-Sternberg MD FANZCA, Fiona Taverner MBBS FANZCA, Prof Andrew Davidson MBBS FANZCA, Justin Skowno MBChB FANZCA, Ben Hallett MBBS FANZCA, David Sommerfield MD FANZCA, Neil Hauser MBChB FANZCA, Tara Williams BN MSN, Susan Spall AssocDipClinTechAnesth, Trang Pham BEng Meng, Tiffany Atkins BASc MBiostat, Mark Jones PhD, Emma King BN, Laura Burgoyne
Tubeless upper airway surgery in children is a complex procedure in which surgeons and anaesthetists share the same operating field. These procedures are often interrupted for rescue oxygen therapy. The efficacy of nasal high-flow oxygen to decrease the frequency of rescue interruptions in children undergoing upper airway surgery is unknown. In this multicentre randomised trial conducted in five tertiary
-
Re-evaluating the role of CPAP in OSA management amid obesity pharmacology advancements Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-17 Neomi Shah
-
Continuous positive airway pressure is here to stay Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-17 Atul Malhotra, Jeremy H Pettus
-
MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-10 Federica Grosso, Luigi Cerbone, Alessandra Curioni-Fontecedro
-
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-10 Prof Eric Lim FRCS, David Waller FRCS, Kelvin Lau FRCS, Jeremy Steele FRCP, Anthony Pope FRCR, Clinton Ali FRCP, Rocco Bilancia FRCS, Manjusha Keni FRCR, Prof Sanjay Popat FRCP, Prof Mary O'Brien FRCP, Nadza Tokaca BM BCh, Prof Nick Maskell FRCP, Louise Stadon BSc, Prof Dean Fennell FRCP, Louise Nelson RGN, John Edwards FRCS, Sara Tenconi FRCS, Laura Socci MD, Prof Robert C Rintoul FRCP, Kelly Wood
Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. MARS 2 was a phase 3, national, multicentre, open-label, parallel two-group, pragmatic, superiority randomised controlled trial
-
Leveraging the pleural space for anticancer therapies in pleural mesothelioma Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-10 Prof Kevin G Blyth MBChB MD, Prof Prasad S Adusumilli MD FACS, Prof Philippe Astoul MD PhD, Liz Darlison MSc, Prof Y C Gary Lee MBChB PhD, Prof Aaron S Mansfield MD, Prof Stefan J Marciniak PhD MBBChir, Prof Nick Maskell BMBS DM, Vasiliki Panou MD PhD, Tobias Peikert MD, Prof Najib M Rahman BMBCh PhD, Marjorie G Zauderer MD MS, Prof Daniel Sterman MD, Prof Dean A Fennell FRCP PhD
Most patients with pleural mesothelioma (PM) present with symptomatic pleural effusion. In some patients, PM is only detectable on the pleural surfaces, providing a strong rationale for intrapleural anticancer therapy. In modern prospective studies involving expert radiological staging and specialist multidisciplinary teams, the population incidence of stage I PM (an approximate surrogate of pleura-only
-
Tackling health disparities in asthma: a life-course challenge Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-08 The Lancet Respiratory Medicine
-
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-05-02 Prof Robert P Frantz MD, Prof Vallerie V McLaughlin MD, Prof Sandeep Sahay MD, Prof Pilar Escribano Subías MD, Prof Ronald L Zolty MD, Prof Raymond L Benza MD, Prof Richard N Channick MD, Prof Kelly M Chin MD, Prof Anna R Hemnes MD, Prof Luke S Howard DPhil, Prof Olivier Sitbon MD, Prof Jean-Luc Vachiéry MD, Prof Roham T Zamanian MD, Matt Cravets MA, Robert F Roscigno PhD, David Mottola PhD, Robin
Morbidity and mortality in pulmonary arterial hypertension (PAH) remain high. Activation of platelet-derived growth factor receptor, colony stimulating factor 1 receptor, and mast or stem cell growth factor receptor kinases stimulates inflammatory, proliferative, and fibrotic pathways driving pulmonary vascular remodelling in PAH. Seralutinib, an inhaled kinase inhibitor, targets these pathways. We
-
US EPA confronts chemical plants’ deadly air pollution Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-25 Bryant Furlow
-
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-24 Prof Anne B Chang PhD, Prof Tom Kovesi MD, Prof Gregory J Redding MD, Conroy Wong MD, Gonzalo G Alvarez MD, Rebecca Nantanda MD, Edgar Beltetón MD, Maynor Bravo-López MD, Prof Maree Toombs PhD, Prof Paul J Torzillo MD, Prof Diane M Gray PhD
Indigenous peoples around the world bear a disproportionate burden of chronic respiratory diseases, which are associated with increased risks of morbidity and mortality. Despite the imperative to address global inequity, research focused on strengthening respiratory health in Indigenous peoples is lacking, particularly in low-income and middle-income countries. Drivers of the increased rates and severity
-
Vitamin A and bronchopulmonary dysplasia: the next steps Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-18 Abhijeet Rakshasbhuvankar, J Jane Pillow
-
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-18 Prof Sascha Meyer MD, Johannes Bay MD, Axel R Franz MD, Prof Harald Ehrhardt MD PhD, Lars Klein MD, Jutta Petzinger MD, Christoph Binder MD, Susanne Kirschenhofer MD, Anja Stein MD, Britta Hüning MD, Axel Heep MD, Eva Cloppenburg MD, Julia Muyimbwa MD, Torsten Ott MD, Julia Sandkötter MD, Norbert Teig MD, Susanne Wiegand MD, Michael Schroth MD, Andrea Kick MD, Donald Wurm MD, Corinna Gebauer MD, Knud
Vitamin A plays a key role in lung development, but there is no consensus regarding the optimal vitamin A dose and administration route in extremely low birthweight (ELBW) infants. We aimed to assess whether early postnatal additional high-dose fat-soluble enteral vitamin A supplementation versus placebo would lower the rate of moderate or severe bronchopulmonary dysplasia or death in ELBW infants
-
New report outlines cost of inaction on AMR ahead of UN high-level meeting Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-18 Talha Burki
-
Lung transplant donors: barriers and ethical considerations Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-17 The Lancet Respiratory Medicine
-
Optimising the approach to ILD diagnosis: the balance of procedural complications against diagnostic accuracy Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-16 Margaret L Salisbury, Kevin R Flaherty
-
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-16 Kirsten A Kalverda MD, Maarten K Ninaber PhD, Lizzy Wijmans PhD, Jan von der Thüsen PhD, René E Jonkers PhD, Johannes M Daniels PhD, Jelle R Miedema MD, Chris Dickhoff PhD, Jürgen Hölters PhD, David Heineman PhD, Merijn Kant MD, Teodora Radonic PhD, Ghada Shahin PhD, Danielle Cohen PhD, Bart Boerrigter PhD, Suzan Nijman MD, Esther Nossent MD, Prof Jerry Braun PhD, Bas Mathot MD, Prof Venerino Poletti
An adequate diagnosis for interstitial lung disease (ILD) is important for clinical decision making and prognosis. In most patients with ILD, an accurate diagnosis can be made by clinical and radiological data assessment, but in a considerable proportion of patients, a lung biopsy is required. Surgical lung biopsy (SLB) is the most common method to obtain tissue, but it is associated with high morbidity
-
European Lung Cancer Congress 2024 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-15 Priya Venkatesan
-
Realignment of clinical research after the COVID-19 era Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-10 Dennis Thomas, Vanessa M McDonald, Peter G Gibson
-
Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-10 Nhung TH Trinh, Annika M Jödicke, Martí Català, Núria Mercadé-Besora, Saeed Hayati, Angela Lupattelli, Daniel Prieto-Alhambra, Hedvig ME Nordeng
-
UK patient with multidrug-resistant tuberculosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-04-09 Tony Kirby
-
-
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-26 Theresa S Ryckman, Nicole Salazar-Austin
-
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-26 Prof Rovina Ruslami PhD, Federica Fregonese PhD, Lika Apriani PhD, Leila Barss MD, Nancy Bedingfield PhD, Victor Chiang BSc, Victoria J Cook MD, Prof Dina Fisher MD, Eri Flores BSc, Prof Greg J Fox PhD, James Johnston PhD, Rachel K Lim MD, Prof Richard Long PhD, Catherine Paulsen MSc, Thu Anh Nguyen PhD, Prof Nguyen Viet Nhung PhD, Diana Gibson MSc, Chantal Valiquette DPS, Andrea Benedetti PhD, Prof
Tuberculosis preventive treatment (TPT) is a key component of tuberculosis elimination. To improve completion and reduce the burden for people and health systems, short, safe, and effective TPT regimens are needed. We aimed to compare safety and treatment completion of various doses and durations of rifampicin in people who were recommended to receive TPT. This partially blinded, parallel-arm, non-inferiority
-
Oral corticosteroids for acute preschool wheeze Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-22 Heidi Makrinioti
-
New framework to define the spectrum of tuberculosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-22 Keertan Dheda, Giovanni Battista Migliori
-
Efficacy of oral corticosteroids for acute preschool wheeze: a systematic review and individual participant data meta-analysis of randomised clinical trials Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-22 Bohee Lee PhD, Prof Steve Turner MBBS, Prof Meredith Borland MBBS, Péter Csonka PhD, Prof Jonathan Grigg MD, Prof Theresa W Guilbert MD, Prof Tuomas Jartti MD, Abraham Oommen MD, Jonathan Twynam-Perkins MBChB, Prof Steff Lewis PhD, Prof Steve Cunningham PhD
Oral corticosteroids are commonly used for acute preschool wheeze, although there is conflicting evidence of their benefit. We assessed the clinical efficacy of oral corticosteroids by means of a systematic review and individual participant data (IPD) meta-analysis. In this systematic review with IPD meta-analysis, we systematically searched eight databases (PubMed, Ovid Embase, CINAHLplus, CENTRAL
-
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-22 Anna K Coussens PhD, Syed M A Zaidi MPH, Brian W Allwood PhD, Puneet K Dewan MD, Prof Glenda Gray MD, Mikashmi Kohli PhD, Tamara Kredo PhD, Prof Ben J Marais PhD, Prof Guy B Marks PhD, Leo Martinez PhD, Morten Ruhwald PhD, Prof Thomas J Scriba PhD, Prof James A Seddon PhD, Phumeza Tisile BA, Prof Digby F Warner PhD, Prof Robert J Wilkinson PhD, Hanif Esmail PhD, Prof Rein M G J Houben PhD, International
The current active–latent paradigm of tuberculosis largely neglects the documented spectrum of disease. Inconsistency with regard to definitions, terminology, and diagnostic criteria for different tuberculosis states has limited the progress in research and product development that are needed to achieve tuberculosis elimination. We aimed to develop a new framework of classification for tuberculosis
-
“Yes! We can end TB,” but remember the sequelae in children Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-22 Esin Nkereuwem, Marieke M van der Zalm, Beate Kampmann, Toyin Togun
-
Ending tuberculosis: ways forward Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-22 The Lancet Respiratory Medicine
-
Genetic factors for ILD—the path of precision medicine Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-20 Ganesh Raghu, Juliet M Torres, Robin L Bennett
-
Early mobilisation in the intensive care unit: shifting from navigating risks to a patient-centred approach Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-18 Hannah Wozniak, Michelle E Kho, Eddy Fan
-
Association of active mobilisation variables with adverse events and mortality in patients requiring mechanical ventilation in the intensive care unit: a systematic review and meta-analysis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-18 Michelle Paton MPhty, Sarah Chan DPhty, Ary Serpa Neto PhD, Claire J Tipping PhD, Anne Stratton BPhty, Prof Rebecca Lane PhD, Lorena Romero MBIT, Tessa Broadley BBiomedSc, Prof Carol L Hodgson PhD
Mobilisation during critical illness is now included in multiple clinical practice guidelines. However, a large, randomised trial and systematic review have recently identified an increased probability of adverse events and mortality in patients who received early active mobilisation in the intensive care unit (ICU). We aimed to determine the effects of mobilisation compared with usual care on adverse
-
Systematic endoscopic staging of mediastinum in locally advanced NSCLC: a SEISMIC change? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-13 Angela Botticella, Antonin Levy, Cécile Le Pechoux
-
Improving rural intensive care infrastructure in the USA Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-12 Tarun Ramesh, Michael Klompas, Hao Yu
-
Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-12 Prof Daniel P Steinfort PhD, Gargi Kothari MBBS, Neil Wallace MBBCh, Nicholas Hardcastle PhD, Kanishka Rangamuwa MBBCh, Edith M T Dieleman MD, Prof Percy Lee MD, Peixuan Li MBiostat, Prof Julie A Simpson PhD, Shaun Yo MBBS, Farzad Bashirdazeh MBBS, Prof Phan Nguyen PhD, Barton R Jennings MBBS, David Fielding MBBS, Laurence Crombag PhD, Prof Louis B Irving MBBS, Prof Kazuhiro Yasufuku PhD, Prof Jouke
Systematic mediastinal lymph node staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) improves accuracy of staging in patients with early-stage non-small-cell lung cancer (NSCLC). However, patients with locally advanced NSCLC commonly undergo only selective lymph node sampling. This study aimed to determine the proportion of patients with locally advanced NSCLC in
-
Charting a course for precision therapy trials in sepsis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-11 Robert B Lindell, Nuala J Meyer
-
MACE in COPD: addressing cardiopulmonary risk Lancet Respir. Med. (IF 38.7) Pub Date : 2024-03-01 John R Hurst, Chris P Gale, Global Working Group on Cardiopulmonary Risk, John R. Hurst, Mohit Bhutani, Jean Bourbeau, MeiLan Han, Nathaniel M. Hawkins, Carolyn S.P. Lam, Darcy D. Marciniuk, David Price, Daiana Stolz, Shelley Zieroth, Chris P. Gale
-
US CDC plans to relax COVID-19 isolation guidelines Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-29 Bryant Furlow
-
Trouble with promoting lung cancer screening in never-smokers – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-28 Chao-Hua Chiu, Chong-Jen Yu, Gee-Chen Chang, Pan-Chyr Yang
-
Trouble with promoting lung cancer screening in never-smokers Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-28 Wayne Gao, H Gilbert Welch
-
Community-acquired pneumonia: the best candidates for clarithromycin – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-28 Evangelos J Giamarellos-Bourboulis, Michael S Niederman
-
Community-acquired pneumonia: the best candidates for clarithromycin Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-28 Yiran Xu, Yun Cai
-
The lung is not a balloon: the self-sealing property of the lung Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-27 Amit Chopra, Marc A Judson, Najib M Rahman, Peter Doelken
-
Risk scores as a surrogate in pulmonary arterial hypertension: a different lens Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-27 R James White, Daniel J Lachant, Raymond L Benza
-
Risk scores as a surrogate in pulmonary arterial hypertension: a different lens – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-27 Michael O Harhay, Bryan S Blette, Steven M Kawut
-
US EPA strengthens PM2·5 air pollution limits Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-23 Bryant Furlow
-
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-23 Prof Manu Shankar-Hari PhD, Prof Thierry Calandra PhD, Prof Miguel P Soares PhD, Prof Michael Bauer MD, Prof W Joost Wiersinga PhD, Hallie C Prescott MD, Prof Julian C Knight DPhil, Prof Kenneth J Baillie FMedSci, Lieuwe D J Bos PhD, Lennie P G Derde PhD, Prof Simon Finfer MD, Prof Richard S Hotchkiss PhD, Prof John Marshall PhD, Prof Peter J M Openshaw FMedSci, Christopher W Seymour MD, Prof Fabienne
Sepsis is a common and deadly condition. Within the current model of sepsis immunobiology, the framing of dysregulated host immune responses into proinflammatory and immunosuppressive responses for the testing of novel treatments has not resulted in successful immunomodulatory therapies. Thus, the recent focus has been to parse observable heterogeneity into subtypes of sepsis to enable personalised
-
Correction to Lancet Respir Med 2024; published online Jan 3. https://doi.org/10.1016/S2213-2600(23)00412-5 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-21
-
A tobacco-free generation: the end goal of the endgame Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-12 The Lancet Respiratory Medicine
-
Tuberculosis, conflict, and displacement Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-07 Talha Burki
-
Thank you to The Lancet Respiratory Medicine's clinical and statistical peer reviewers in 2023 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-01-30
Abstract not available
-
Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-01 Prof Nicholas Heming MD, Alain Renault MSc, Emmanuelle Kuperminc MD, Prof Christian Brun-Buisson MD, Prof Bruno Megarbane MD, Prof Jean-Pierre Quenot MD, Shidasp Siami MD, Prof Alain Cariou MD, Xavier Forceville MD, Prof Carole Schwebel MD, Prof Marc Leone MD, Prof Jean-Francois Timsit MD, Prof Benoît Misset MD, Mohamed Ali Benali MD, Gwenhael Colin MD, Prof Bertrand Souweine MD, Prof Karim Asehnoune
Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock. APROCCHSS
-
Corticosteroids in septic shock secondary to community acquired pneumonia: clarity mixed with uncertainty Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-01 Balasubramanian Venkatesh, Jeremy Cohen
Abstract not available
-
Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-01 Elisa Puzzolo PhD, Nigel Fleeman MPH, Federico Lorenzetti MSc, Fernando Rubinstein MD, Yaojie Li MSc, Ran Xing MSc, Guofeng Shen PhD, Emily Nix PhD, Michelle Maden PhD, Rebecca Bresnahan PhD, Rui Duarte PhD, Lydia Abebe PhD, Jessica Lewis PhD, Kendra N Williams PhD, Heather Adahir-Rohani MPH, Prof Daniel Pope PhD
Exposure to household air pollution from polluting domestic fuel (solid fuel and kerosene) represents a substantial global public health burden and there is an urgent need for rapid transition to clean domestic fuels. Gas for cooking and heating might possibly affect child asthma, wheezing, and respiratory health. The aim of this review was to synthesise the evidence on the health effects of gaseous
-
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-01 John Norrie
Abstract not available
-
Transitioning to gaseous and liquid fuels: a right step towards clean cooking in low-income and middle-income countries Lancet Respir. Med. (IF 38.7) Pub Date : 2024-02-01 Anindita Dutta, Christopher O Olopade
Abstract not available